; (bb) the development of alternative dosage forms and strengths for the prescription drug molecule or combinations, including the molecule; (cc) other prescription drug development activities, such as nonclinical laboratory studies and record and report maintenance; (dd) pursuing new or expanded indications for such prescription drug through supplemental applications under such section 505 or such section 351; (ee) carrying out postmarket requirements related to such prescription drug, including under subsection (o) of such section 505 or such section 351; (ff) carrying out risk evaluation and mitigation strategies in accordance with section 505–1 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355–1 ) or such section 351; and (gg) marketing research; (II) the acquisition of prescription drug components and packaging, in total and per unit sold, broken out by source and cost and identifying specific costs that reflect internal transfers within the manufacturer’s company; (III) other acquisitions relating to the prescription drug, including for the purchase of patents and licensing or acquisition of any corporate entity owning any rights to the drug during or after development of the prescription drug; (IV) the cost of manufacturing the prescription drug; (V) marketing, advertising, and educating for the promotion of a prescription drug, including a breakdown of amounts aimed at consumers, prescribers, managed care organizations, and others, irrespective of whether a prescription drug is mentioned in marketing, advertising, or educating; and (VI) patient assistance and co-pay programs that the manufacturer sponsors or contributes to. (viii) The gross revenue, net revenue, gross profit, and net profit of the manufacturer with respect to such prescription drug. (ix) The total number of units of such prescription drug that were sold in interstate commerce. (x) Pricing information with respect to the sale of such prescription drug, including— (I) the current wholesale acquisition cost